Supplementary materials: Effectiveness of bisoprolol versus other β-blockers and other antihypertensive classes: a cohort study in the Clinical Practice Research Datalink

dataset

posted on 2024-05-03, 10:09 authored by Caroline Foch, Arthur Allignol, Thilo Hohenberger, Emmanuelle Boutmy, Stephan Schaefer, Ulrike Hostalek

These are peer-reviewed supplementary materials for the article 'Effectiveness of bisoprolol versus other β-blockers and other antihypertensive classes: a cohort study in the Clinical Practice Research Datalink' published in the Journal of Comparative Effectiveness Research.

Supplementary Figure 1: A model showing the progress of each patient through different hypertension states over time.
Supplementary Table 1: Antihypertensive drugs considered for each treatment of interest.
Supplementary Figure 2: Patient attrition and the number of patients in each analysis set.
Supplementary Table 2: Baseline characteristics before matching, in patients fulfilling the study criteria.
Supplementary Table 3: Baseline comorbidities and comedications, in patients fulfilling the study definition.
Supplementary Table 4: Baseline characteristics of all analysis sets, post-matching. A. Baseline characteristics and comedications after matching, in the T2DM analysis set.
Supplementary Figure 3: Distribution of the propensity scores, after matching.
Supplementary Table 5: Standardized mean differences before/after matching.
Supplementary Table 6: Transition intensities for the multi-state model between controlled and uncontrolled BP states, length of stay in the controlled state, after matching in the BP analysis set.
Supplementary Table 7: Number of events and safety event incidence rates after matching, for each event of interest and comparison group.
Supplementary Table 8: Cause-specific Cox proportional hazards models and Fine and Gray models for T2DM – sensitivity analysis excluding patients with prior impaired fasting blood glucose levels.
Supplementary Table 9: Cause-specific Cox proportional hazards models and Fine and Gray models for competing events of outcome for interest.

Aim: To compare blood pressure (BP) and safety outcomes in patients with hypertension initiating bisoprolol, versus other β-blockers, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, calcium channel blockers or diuretics. Materials & methods: New user cohort study. Patients initiating bisoprolol were matched with up to four patients, in each comparator cohort using propensity score. BP outcomes were compared using linear mixed models and safety outcomes using Cox proportional hazards. Results: Differences in average systolic and diastolic BP variation were ≤3 mmHg between bisoprolol versus the compared classes. No difference was observed in risk of diabetes, obesity or erectile dysfunction. An increased dyslipidemia risk was only observed versus diuretics (hazard ratio: 0.76; 98.75% CI: 0.58, 0.99). Conclusion: No differences in BP variation and safety outcomes.